Ocugen spikes as Oppenheimer issues new Outperform on upcoming catalysts
Source: SeekingAlpha
2026-03-11 11:45:11 ET
More on Ocugen
- Ocugen: Downgrading After OCU410 Data Release
- Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript
- Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data
- Ocugen outlines 2026 BLA submission and expects three pivotal filings within three years amid leadership expansion
- Ocugen GAAP EPS of -$0.06 in-line
Read the full article on Seeking Alpha
For further details see:
Ocugen spikes as Oppenheimer issues new Outperform on upcoming catalysts
Ocugen, Inc.
NASDAQ: OCGN
OCGN Trading
29.81% G/L:
$2.2781 Last:
29,572,745 Volume:
$1.84 Open:
OCGN Latest News
March 04, 2026 08:15:00 am
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
OCGN Stock Data
$478,717,026
313,395,708
0.26%
38
N/A
Biotechnology & Life Sciences
Healthcare
US
Malvern
